Manufacturer
NOVARTIS PHARMA AG
Contents
Pasireotide
Indication
Acromegaly in adult patients for whom surgery is not an option or has not been curative & who are inadequately controlled on treatment w/ another somatostatin analogue. Cushing's disease in adult patients for whom surgery is not an option or for whom surgery has failed.
Instruction
Administer via deep IM Injection
Drug interaction
Decreased relative bioavailability of ciclosporin. Use w/ caution when co-administered w/ medicinal products known to prolong QT interval eg, class Ia antiarrhythmics (eg, quinidine, procainamide, disopyramide), class III antiarrhythmics (eg, amiodarone, dronedarone, sotalol, dofetilide, ibutilide), certain antibacterials (IV erythromycin, pentamidine inj, clarithromycin, moxifloxacin), certain antipsychotics (eg, chlorpromazine, thioridazine, fluphenazine, pimozide, haloperidol, tiapride, amisulpride, sertindole, methadone), certain antihistamines (eg, terfenadine, astemizole, mizolastine), antimalarials (eg, chloroquine, halofantrine, lumefantrine), certain antifungals (ketoconazole, except in shampoo). Clinical monitoring of heart rate is recommended when concomitantly receiving bradycardic medicinal products eg, β-blockers (eg, metoprolol, carteolol, propranolol, sotalol), acetylcholinesterase inhibitors (eg, rivastigmine, physostigmine), certain Ca channel blockers (eg, verapamil, diltiazem, bepridil), certain antiarrhythmics. Dose adjustments of insulin & antidiabetic medicinal products (eg, metformin, liraglutide, vildagliptin, nateglinide) may be required.
Malaysia
